Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine.

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Uwe PlatzbeckerGroupe Francophone des Myelodysplasies

Abstract

Standard first-line therapy for older patients with high-risk myelodysplastic syndrome (MDS) includes hypomethylating agents, such as azacitidine (AZA). However, the only approach with curative potential remains allogeneic hematopoietic cell transplantation (HCT). To date, no direct comparison of both strategies has been reported. The outcomes of 2 well-balanced cohorts of patients with high-risk MDS defined by age (60-70 years), performance status (Eastern Cooperative Oncology Group score ≤2), and donor availability (yes/no) were compared, including 103 patients undergoing HCT and 75 patients without this option who received AZA. The estimated 2-year overall survival after the start of treatment was 39% (95% confidence interval, 30%-50%) for the patients undergoing HCT and 23% (95% confidence interval, 14%-40%) for the patients receiving AZA therapy. In a multivariate Cox regression analysis of all patients (n = 178), Eastern Cooperative Oncology Group score (0 versus 1 versus 2; hazard ratio [HR], 2.9/3.9; P <  .001), cytogenetics (good versus intermediate versus poor; HR, 1.2/1.7; P = .026), and treatment (HCT versus AZA; HR, 0.3; P = .007) were associated with overall survival. This retrospective cohort analysis suggests a ...Continue Reading

References

Apr 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hartmut BertzJürgen Finke
Apr 7, 2006·Blood·Rodrigo MartinoUNKNOWN Myelodysplastic Syndrome subcommittee of the Chronic Leukemia Working Party of the European Blood and Marrow Transplantation
May 29, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Philippe ArmandRobert J Soiffer
Apr 23, 2009·Blood·Richard M Stone
Aug 5, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Olle RingdénVanderson Rocha
Dec 17, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ziyi LimTheo M De Witte
Mar 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian L McCluneSergio Giralt

❮ Previous
Next ❯

Citations

Feb 26, 2013·Current Treatment Options in Oncology·Karen Seiter
Oct 5, 2013·Current Hematologic Malignancy Reports·Katja Sockel, Uwe Platzbecker
Feb 11, 2014·Best Practice & Research. Clinical Haematology·Uwe Platzbecker, Ghulam Mufti
Aug 21, 2013·Blood Reviews·Amer M ZeidanSteven D Gore
Dec 3, 2014·Hematology/oncology Clinics of North America·Katrin Wetzko, Uwe Platzbecker
Nov 7, 2013·Expert Review of Hematology·Drorit G Merkel, Arnon Nagler
Aug 1, 2014·Expert Opinion on Pharmacotherapy·Vu H DuongAlan F List
Jan 1, 2014·Journal of Clinical Medicine·Marjan CruijsenGerwin Huls
Feb 19, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Taiga NishihoriTeresa Field
Jun 25, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Andrew M BrunnerYi-Bin Chen
Jul 23, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Michael R Grunwald
Aug 21, 2014·Leukemia Research·M Díez CampeloUNKNOWN Spanish Registry of MDS
Oct 30, 2012·Molecular Oncology·Angela NebbiosoLucia Altucci
Dec 24, 2013·Blood·Mikkael A Sekeres, Corey Cutler
Jun 21, 2016·Bone Marrow Transplantation·M R GrunwaldE A Copelan
Aug 16, 2016·Clinical Lymphoma, Myeloma & Leukemia·Asmita Mishra, Claudio Anasetti
Oct 25, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Silke HeidenreichNicolaus Kröger
Jun 26, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John KorethCorey Cutler
Jan 24, 2019·Blood·Uwe Platzbecker
Mar 31, 2020·Current Hematologic Malignancy Reports·Shukaib Arslan, Ryotaro Nakamura
Dec 7, 2019·Hematology·Guillermo F Sanz
Dec 5, 2013·Deutsches Ärzteblatt International·Ulrich GermingNorbert Gattermann
Jan 12, 2021·Blood Reviews·Caner Saygin, Hetty E Carraway

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

© 2021 Meta ULC. All rights reserved